Advice
in the absence of a submission from the holder of the marketing authorisation:
baloxavir marboxil (Xofluza®) is not recommended for use within NHSScotland.
Indication under review: post-exposure prophylaxis of influenza in individuals aged 3 weeks and above.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice212KB (PDF)
Medicine details
- Medicine name:
- baloxavir marboxil (Xofluza)
- SMC ID:
- SMC2921
- Indication:
Post-exposure prophylaxis of influenza in individuals aged 3 weeks and above
- Pharmaceutical company
- Roche
- BNF chapter
- Respiratory system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 April 2026